A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
NCT06857942 on ClinicalTrials.gov · last registry update 2026-06-03
An unusually large phase 4: 200 participants, more than double the 72 typical for the stage. Due to report May 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) (0,1). Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P4
- Drug
- tirzepatideZepbound, Mounjaro
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 200
- Started
- 2025-03-19
- Primary completion
- 2028-05 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) (0,1)
Conditions studied
Psoriasis · Overweight or Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.